Compositions and methods for treating idiopathic pulmonary fibrosis
AssigneeSeyltx, Inc.
InventorMark Williams
Life of this patent
Estimating the term…
Abstract
The use of pharmaceutically active compounds for treating chronic lung diseases including idiopathic pulmonary fibrosis is disclosed. The compounds include NMDA receptor antagonists, glutamate 2b receptor antagonists and sigma receptor agonists. In particular, the use of bromantane, ifenprodil, radiprodil, bemithyl and repirinast are effective in treating idiopathic pulmonary fibrosis. Methods of use thereof are also disclosed.
Claims16
A method for the treatment or prophylaxis of interstitial lung disease in a subject comprising administering an effective amount of ifenprodil to the subject, wherein the method does not comprise administration of an NMDA receptor antagonist other than ifenprodil.
A method for the treatment or prophylaxis of interstitial lung disease in a subject comprising administering an effective amount of ifenprodil or a pharmaceutically acceptable variation thereof to the subject, wherein the ifenprodil or the pharmaceutically acceptable variation thereof is ifenprodil hemitartrate, wherein the method does not comprise administration of an NMDA receptor antagonist other than ifenprodil or the pharmaceutically acceptable variation thereof.
Dependencies are inferred from the claim text.